Stock Pitch Examples for Hedge Fund Interviews

When you sit down for a hedge fund interview, the stock pitch isn't one question among many. It's the conversation. In banking, a pitch can win you points at the margin, a nice signal that you understand valuation and think like an investor. On the buy side, it's the whole audition. Most funds will ask you for two to four pitches across the process, and they will expect you to know those companies cold. Not "I read a sell-side note once" cold. "Ask me anything about the unit economics and I'll have an answer" cold. You have been warned.

That changes how you should think about preparing. The single most important thing I can tell you is this: in a hedge fund pitch, the thesis section is the part that matters most, and it has to show analysis rather than assert it. An interviewer is not going to wait three months to find out whether your price target was right. What they can evaluate, right now, in the room, is whether you did real work. So the example you bring has to carry the weight of that work on its face.

This article is about what a hedge-fund-grade pitch example actually looks like. I'll walk you through two fully worked examples, both labeled hypothetical, so you can see exactly where the depth lives and how to build your own to the same standard. (If you want the broader breakdown of how a buy-side pitch differs structurally from a banking one, that's its own subject; here I want to demonstrate the depth rather than describe it.)

Why the example is the whole game

Banking interviewers usually ask one or two simple follow-ups after a pitch, often just clarifying a point. They're testing conceptual understanding, not your investor mindset, and unless your thesis is confusing or plainly wrong, they don't dig much deeper. A hedge fund interviewer does the opposite. Expect numerous follow-ups on the justification behind every thesis, the comparable companies and precedent transactions you leaned on, the assumptions in your DCF, the competitive landscape, your company's total addressable market, and your reasoning on risks and mitigants.

That's why the example does all the work. A vague pitch invites the interviewer to poke holes; a precise, numbers-backed pitch invites them to follow you down a path you've already mapped. The best investors tell a story with their numbers, and the example you bring should read like a short, confident story with a clear protagonist, a clear mispricing, and a clear reason the market is wrong. If you want a feel for how to frame a narrative around a valuation, Aswath Damodaran's YouTube videos are excellent on exactly this. He's a master at making the numbers tell a story rather than the other way around.

A hedge fund pitch should still run the same shape as any other: a clear recommendation, a quick company overview, the competitive advantage and thesis, the market context, catalysts, a price target, and the risks with their mitigants. Aim for somewhere between a minute and a half and two and a half minutes of actual talking. What's different is the density. Every section is doing more.

What "hedge fund grade" actually means

The cleanest version of this I've ever used was a long where the whole thesis came down to a single mispriced assumption: the street was modeling a retailer's gross margin and SG&A incorrectly after a price increase, and bridging that specific street-versus-mine gap produced a quantified free-cash-flow delta over the forecast period. That's the template to internalize. Find a number the consensus has wrong, rebuild it from the bottom up, and translate the difference into cash. Everything below is built to that standard.

Let me show you two. The first is a long; the second is a short, to prove the pattern generalizes. Both companies are invented for teaching purposes, but the numbers are internally consistent and the method is exactly what you'd do with a real name.

Worked example #1: a hypothetical long

Imagine a hypothetical mid-cap household-products company. I'll call it Company A. It makes branded cleaning and personal-care products sold through grocery and mass retail. It trades at $36, generates roughly $1.5b of revenue, carries about $0.4b of net debt, and has around 58m shares outstanding. The story: eighteen months ago, a spike in input costs (resins, surfactants, packaging) crushed gross margins, and the street has extrapolated that pain forward, modeling gross margin stuck around 40% for years. The stock has been left for dead as a low-margin commodity play.

Here's how I'd open the pitch.

"I'm recommending a long on Company A over a roughly eighteen-month horizon, with a target of $48 against today's $36, about 33% upside. The market is treating last year's input-cost spike as permanent and pricing the stock as if gross margins are stuck near 40% forever. My work says that's wrong: input costs are already normalizing, a price increase Company A pushed through last quarter is sticking, and gross margin recovers to the mid-44% range. The street hasn't updated for it yet, and that's the gap I'm playing."

Notice what that recommendation does. It states the position, the horizon, the target, the upside, and the single load-bearing reason the market is wrong, all in a few sentences. Now the company overview, kept tight and pointed toward the "why":

"Company A sells branded household and personal-care products, number two in its core category behind a much larger peer, with about $1.5b in revenue growing low single digits. Roughly two-thirds of sales are everyday consumables, so volumes are sticky across the cycle. The reason it's trading where it is: input costs spiked eighteen months ago, gross margin fell from the mid-40s into the low 40s, and after the company guided cautiously, the street modeled that compression as the new normal. What they're missing is that the cost spike was transitory and the company has pricing power it hasn't been credited for."

Then the heart of it: the competitive advantage and the quantified thesis. This is where you earn the offer.

"My conviction rests on two things the street has modeled incorrectly. First, gross margin. The street has Company A at about 40% gross margin going forward. I rebuilt the margin bottom-up: I took the cost per unit at the old input-price levels, normalized resin and packaging costs back toward their pre-spike trend, and layered in the 6% list-price increase that's already in market and holding. That gets me to roughly 44% gross margin, four points above the street. On $1.5b of revenue, four points is about $60m of incremental gross profit a year.

Second, SG&A. The street models SG&A as a flat percentage of sales, so as revenue grows they let costs grow right alongside it. But the bulk of Company A's SG&A is fixed: distribution centers, the core sales force, brand marketing that doesn't scale one-for-one with volume. Modeled correctly on a fixed-plus-variable basis, SG&A grows slower than revenue, and that operating leverage is worth roughly another $20m a year versus the street.

Put those together and I'm carrying EBITDA margin around 23.5% versus the street's 18%. On $1.5b that's about $352m of EBITDA against their $270m, an $80m-a-year gap. Tax-effected and run across my three-year forecast period, that's roughly $180m of incremental unlevered free cash flow the street isn't modeling."

That is the difference between a banking pitch and a buy-side pitch in one block. You didn't say "margins will improve." You said by how much, why the consensus method is wrong, and what the cash gap is. Every sentence is something you can defend.

Now tie the catalyst to the horizon you named up front, because a thesis with no catalyst is just an opinion:

"The catalyst is the next two or three earnings prints. Gross margin recovery shows up first in the upcoming quarter as the priced-through increase flows over normalizing costs, and I'd expect management to start raising full-year margin guidance. That's the moment the street is forced to re-rate its model, and it lines up directly with my twelve-to-eighteen-month horizon."

Then the price target, derived so it's defensible the second they ask:

"I get to my $48 target on about 9 times EV/EBITDA, in line with where the branded peers trade. Nine times my $352m of EBITDA is roughly $3.17b of enterprise value; net of $0.4b of debt and across 58m shares, that's about $48 a share. The sanity check on the downside is reassuring: 9 times the street's $270m, less the same net debt, gets you to about $35, which is essentially where the stock trades today. So the market is paying for the street's numbers. I'm getting paid for being right on the margin."

That last move is worth dwelling on. By showing that today's price corresponds to the consensus EBITDA at the same multiple, you've proven the stock isn't expensive on your view; it's the margin call that creates the upside, not multiple expansion you'd have to defend separately. Finally, the risk and its mitigant, because the interviewer will want to know why you're still long despite the obvious risk:

"The main risk is that input costs spike again before the margin recovery is visible, which would muddy the print and delay the re-rate. The mitigant is that roughly a year of forward input needs are hedged, so a fresh spike wouldn't hit the P&L until well after my catalysts have played out. And because the stock is already priced at the street's depressed margin, I'm not paying up for a recovery that hasn't happened, which limits how much further it can fall on a bad headline."

Worked example #2: a hypothetical short

Longs are easier to fall in love with, so it helps to have a short ready too. The mechanics are the same, but the mispricing usually lives in growth and multiple rather than margin. Imagine a hypothetical mid-cap vertical-software company. Call it Company B. It trades at $90, with about 80m shares for a roughly $7.2b market cap and roughly $180m of net cash, on around $600m of next-twelve-month revenue, so about 12 times forward revenue. The bulls own it because it has compounded at 25% for years.

"I'm pitching a short on Company B over a twelve-month horizon, with a target of $60 against today's $90, about 33% downside. The market is paying 12 times forward revenue for sustained mid-20s growth. My work says growth is about to halve, and when it does, both the numbers and the multiple come down at the same time."

The thesis is the deceleration, quantified:

"Company B's growth has been carried by net revenue retention, existing customers spending more each year. NRR has run around 118%, meaning even with zero new logos the base grows 18%. But the cohort data is rolling over: seat counts in the customer base are flat, upsell modules are saturating, and the last two quarters show NRR drifting toward the low 110s. I model it settling near 104% within a year. That alone takes total growth from the street's 20% next year to roughly 10%. So instead of the street's $720m for the following year, I'm at about $660m.

The second leg is the multiple. A 12 times revenue multiple is a growth multiple. When a software company decelerates from the mid-20s into the low double digits, the comp set it gets valued against changes entirely, and those names trade closer to 7 times. So I'm marking down both the revenue and the multiple at once. Seven times my $660m, plus the $180m of net cash, across 80m shares, is about $60 a share. That's my target, and it's 33% below today."

Catalyst, risk, and mitigant follow the same discipline:

"The catalyst is the next two earnings prints, where I expect NRR and net-new ARR to disappoint and guidance to come down. The biggest risk to the short is a takeout, since strategic acquirers do pay up for installed bases like this. But the mitigant is that the stock is already priced for perfection at 12 times, so the bar for a premium bid is high, and my twelve-month window is short enough that I'm not exposed to years of multiple support."

How a strong example pre-empts the valuation follow-ups

On the buy side, a large share of the follow-ups after your pitch will be about valuation: the comps you chose, the precedent transactions, the assumptions in your DCF, the TAM, how competitors are faring. Put extra focus there if you're interviewing for these seats. The good news is that a properly built example pre-empts most of those questions, because you've already shown your work.

Look back at Company A. The moment you say "9 times EV/EBITDA, in line with branded peers," you've invited and simultaneously answered "what multiple did you use and why." When you say "I rebuilt the margin bottom-up from unit costs," you've answered "how did you get to 44%." The trick that experienced pitchers use is to drop a number large enough to be irresistible, like that ~$180m of incremental free cash flow, knowing the interviewer will ask you to walk through it, and then hand them the analysis you've already prepared rather than improvising under pressure. You're choosing the question they'll ask.

If you want to see what real, professional-grade write-ups look like, the buy-side community publishes them. Value Investors Club (valueinvestorsclub.com) and the hedge fund presentations on 10xebitda.com are both worth studying for how practitioners structure conviction. The specifics of where to mine those examples is its own topic, but a few hours reading real theses will teach you more about texture and depth than any amount of advice.

Bringing it together

A hedge-fund-grade example isn't a longer banking pitch. It's a different artifact. It names a specific consensus number, rebuilds that number from the ground up, quantifies the gap in cash flow or multiple, ties a catalyst to a horizon, and arrives at a price target you can derive on demand. Build one long and one short to that standard, know them well enough to survive ten follow-ups each, and have a third and fourth ready because they'll ask. Do that, and the pitch stops being the thing you're nervous about and becomes the thing you're hoping they ask for.